Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAM2029 vs Octreotide LAR or Lanreotide ATG in GEP-NET
NCT05050942Phase 3Active, not recruiting
- Sponsor
- Camurus
- Start
- Oct 2021
- Primary completion
- Nov 2026
- Modality
- Peptides
- Countries
- 12
01
Overview
A Phase 3 trial of octreotide hydrochloride in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Camurus. Started Oct 2021; status: active, not recruiting.
02
Drugs
octreotide hydrochloride
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT05050942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05050942.